Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hayrettin Tumani

Showing results (1-10 of 289) with videos related to

Pageof 29
Sort By:
Journal of Neurology|September 26, 2006
Rare indications of IVIG therapy in neurological diseases based on case reports and small studiesHayrettin Tumani
Journal of Neurology|May 16, 2007
Influences on cognition by immunosuppression and immunomodulation in multiple sclerosisHayrettin Tumani, Ingo Uttner
Neurology|January 21, 2012
Patterns of intrathecal autoreactive antibodies in MS using antigen microarraysThomas Korn, Hayrettin Tumani
Neurology|March 23, 2011
Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis?Hayrettin Tumani, Diego Cadavid
Handbook of Clinical Neurology|November 8, 2017
EpilepsySusanne Fauser, Hayrettin Tumani
Current Pharmaceutical Design|May 23, 2012
Biochemical markers of autoimmune diseases of the nervous systemHayrettin Tumani, Johannes Brettschneider
Handbook of Clinical Neurology|November 8, 2017
The cerebrospinal fluid and barriers - anatomic and physiologic considerationsHayrettin Tumani, André Huss, Franziska Bachhuber
Frontiers in Neurology|June 17, 2017
Primary Progressive Multiple Sclerosis: Putting Together the PuzzleAhmed Abdelhak, Martin S Weber, Hayrettin Tumani
Handbook of Clinical Neurology|November 8, 2017
PrefaceFlorian Deisenhammer, Charlotte E Teunissen, Hayrettin Tumani
Therapeutic Advances in Neurological Disorders|June 23, 2021
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesHela-Felicitas Petereit, Hayrettin Tumani, Uwe K Zettl
Pageof 29

Showing results (1-10 of 289) with videos related to

Sort By:
Pageof 29
Journal of Neurology|September 26, 2006
Rare indications of IVIG therapy in neurological diseases based on case reports and small studiesHayrettin Tumani
Journal of Neurology|May 16, 2007
Influences on cognition by immunosuppression and immunomodulation in multiple sclerosisHayrettin Tumani, Ingo Uttner
Neurology|January 21, 2012
Patterns of intrathecal autoreactive antibodies in MS using antigen microarraysThomas Korn, Hayrettin Tumani
Neurology|March 23, 2011
Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis?Hayrettin Tumani, Diego Cadavid
Handbook of Clinical Neurology|November 8, 2017
EpilepsySusanne Fauser, Hayrettin Tumani
Current Pharmaceutical Design|May 23, 2012
Biochemical markers of autoimmune diseases of the nervous systemHayrettin Tumani, Johannes Brettschneider
Handbook of Clinical Neurology|November 8, 2017
The cerebrospinal fluid and barriers - anatomic and physiologic considerationsHayrettin Tumani, André Huss, Franziska Bachhuber
Frontiers in Neurology|June 17, 2017
Primary Progressive Multiple Sclerosis: Putting Together the PuzzleAhmed Abdelhak, Martin S Weber, Hayrettin Tumani
Handbook of Clinical Neurology|November 8, 2017
PrefaceFlorian Deisenhammer, Charlotte E Teunissen, Hayrettin Tumani
Therapeutic Advances in Neurological Disorders|June 23, 2021
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesHela-Felicitas Petereit, Hayrettin Tumani, Uwe K Zettl
Pageof 29